Northwest Biotherapeutics (NWBO) Operating Income (2016 - 2025)
Historic Operating Income for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$14.3 million.
- Northwest Biotherapeutics' Operating Income rose 324.98% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 278.38%. This contributed to the annual value of -$66.5 million for FY2024, which is 1981.7% down from last year.
- According to the latest figures from Q3 2025, Northwest Biotherapeutics' Operating Income is -$14.3 million, which was up 324.98% from -$14.8 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Operating Income registered a high of -$10.0 million during Q3 2021, and its lowest value of -$21.1 million during Q2 2022.
- Its 5-year average for Operating Income is -$15.2 million, with a median of -$14.8 million in 2024.
- Examining YoY changes over the last 5 years, Northwest Biotherapeutics' Operating Income showed a top increase of 7901.08% in 2021 and a maximum decrease of 14984.04% in 2021.
- Northwest Biotherapeutics' Operating Income (Quarter) stood at -$10.7 million in 2021, then tumbled by 70.27% to -$18.2 million in 2022, then increased by 16.7% to -$15.1 million in 2023, then dropped by 22.17% to -$18.5 million in 2024, then increased by 22.59% to -$14.3 million in 2025.
- Its Operating Income stands at -$14.3 million for Q3 2025, versus -$14.8 million for Q2 2025 and -$17.3 million for Q1 2025.